However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...